CSIMarket
 


Celgene Corp  (CELG)
Other Ticker:  
 
 

CELG's Capital Expenditures Growth by Quarter and Year

Celgene's Capital Expenditures results by quarter and year




CELG Capital Expenditures (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - 98.00 103.00 66.40
III Quarter September 468.00 64.00 44.00 66.50
II Quarter June 60.00 80.00 70.00 43.70
I Quarter March 69.00 88.00 62.00 59.60
FY   597.00 330.00 279.00 236.20



CELG Capital Expenditures third quarter 2019 Y/Y Growth Comment
Celgene Corp showed record Capital Expenditures surge in the third quarter with 631.25% from the third quarter 2018, to $ 468.00 millions.

Looking into third quarter results within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Capital Expenditures growth. While Celgene Corp' s Capital Expenditures doubling of 631.25% ranks overall at the positon no. 153 in the third quarter.




CELG Capital Expenditures ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - -4.85 % 55.12 % -52.84 %
III Quarter September 631.25 % 45.45 % -33.83 % 397.01 %
II Quarter June -25 % 14.29 % 60.18 % -17.08 %
I Quarter March -21.59 % 41.94 % 4.03 % 40.9 %
FY   - 18.28 % 18.12 % -5.21 %

Financial Statements
Celgene's third quarter 2019 Capital Expenditures $ 468.00 millions CELG's Income Statement
Celgene's third quarter 2018 Capital Expenditures $ 64.00 millions Quarterly CELG's Income Statement
New: More CELG's historic Capital Expenditures Growth >>


CELG Capital Expenditures (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - 53.13 % 134.09 % -0.15 %
III Quarter September 680 % -20 % -37.14 % 52.17 %
II Quarter June -13.04 % -9.09 % 12.9 % -26.68 %
I Quarter March -29.59 % -14.56 % -6.63 % -57.67 %
FY (Year on Year)   - 18.28 % 18.12 % -5.21 %




Capital Expenditures third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #44
Overall #153

Capital Expenditures Y/Y Growth Statistics
High Average Low
631.25 % 34.21 % -100 %
(Sep 30 2019)   (Dec 31 2011)
Capital Expenditures third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #44
Overall #153
Capital Expenditures Y/Y Growth Statistics
High Average Low
631.25 % 34.21 % -100 %
(Sep 30 2019)   (Dec 31 2011)

Capital Expenditures by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Celgene's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
952.24 % 47.62 % -100 %
(Dec 31 2015)  


CELG's III. Quarter Q/Q Capital Expenditures Comment
Celgene Corp achieved in the III. Quarter 2019 above company average sequential Capital Expenditures doubling of 680%, to $ 468.00 millions, from $60.00 millions in the second quarter.
CELG is undergoing a remarkable growth, with claiming higher then average increase, and additionally improving speed, Joana Pinto Oliveira, Healthcare sector expert said.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Celgene's Capital Expenditures growth quarter on quarter, overall rank is 85.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #26
Overall #85
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #26
Overall #85
Capital Expenditures Q/Q Growth Statistics
High Average Low
952.24 % 47.62 % -100 %
(Dec 31 2015)  


CELG's III. Quarter Q/Q Capital Expenditures Comment
Celgene Corp achieved in the III. Quarter 2019 above company average sequential Capital Expenditures doubling of 680%, to $ 468.00 millions, from $60.00 millions in the second quarter.
Major Pharmaceutical Preparations company is impressively improving, not just recording higher then average gain, and also increasing rate, Joana Pinto Oliveira, Healthcare sector expert mentioned.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Celgene's Capital Expenditures growth quarter on quarter, overall rank is 85.


Celgene's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
Cumulative Capital Expenditures 12 Months Ending $ 695.00 $ 291.00 $ 311.00 $ 330.00 $ 335.00
Y / Y Capital Expenditures Growth (TTM) 107.46 % -7.62 % 1.97 % 18.28 % 38.2 %
Year on Year Capital Expenditures Growth Overall Ranking # 429 # 754 # 768 # 1392 # 900
Seqeuential Capital Expenditures Change (TTM) 138.83 % -6.43 % -5.76 % -1.49 % 6.35 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 84 # 1981 # 974 # 2014 # 1297




Cumulative Capital Expenditures growth Comment
Although Celgene's Annual Capital Expenditures growth year on year were below company's average 141.06% , Capital Expenditures announced in the Sep 30 2019 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 107.46% year on year, from -7.62% in Jun 30 2019.

In the Healthcare sector 86 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 429, from total ranking in previous quarter at 754.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1560.21 %
54.58 %
-23.95 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 87
Overall # 429

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3419.24 %
141.06 %
-21.96 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 20
S&P 500 # 84
Cumulative Capital Expenditures growth Comment
Although Celgene's Annual Capital Expenditures growth year on year were below company's average 141.06% , Capital Expenditures announced in the Sep 30 2019 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 107.46% year on year, from -7.62% in Jun 30 2019.

In the Healthcare sector 86 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 429, from total ranking in previous quarter at 754.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1560.21 %
54.58 %
-23.95 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 87
Overall # 429

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3419.24 %
141.06 %
-21.96 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 20
S&P 500 # 84




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CELG's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CELG's Competitors
Capital Expenditures Growth for Celgene's Suppliers
Capital Expenditures Growth for CELG's Customers

You may also want to know
CELG's Annual Growth Rates CELG's Profitability Ratios CELG's Asset Turnover Ratio CELG's Dividend Growth
CELG's Roe CELG's Valuation Ratios CELG's Financial Strength Ratios CELG's Dividend Payout Ratio
CELG's Roa CELG's Inventory Turnover Ratio CELG's Growth Rates CELG's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2019
Chembio Diagnostics Inc 1,063.37%$ 1,063.367 millions
X4 Pharmaceuticals Inc1,057.14%$ 1,057.143 millions
Veru Inc 1,034.85%$ 1,034.855 millions
Corbus Pharmaceuticals Holdings Inc 1,028.74%$ 1,028.738 millions
Arrowhead Pharmaceuticals Inc 1,003.77%$ 1,003.769 millions
Allogene Therapeutics Inc 861.84%$ 861.840 millions
Xtant Medical Holdings Inc 860.00%$ 860.000 millions
Eagle Pharmaceuticals inc 821.21%$ 821.212 millions
Lifevantage Corp774.42%$ 774.419 millions
Pacific Biosciences Of California Inc 763.54%$ 763.542 millions
Genocea Biosciences Inc 758.97%$ 758.974 millions
Adma Biologics Inc 756.52%$ 756.518 millions
Charles River Laboratories International inc 746.82%$ 746.819 millions
Tearlab Corp740.00%$ 740.000 millions
Bionik Laboratories Corp 734.01%$ 734.006 millions
Akebia Therapeutics Inc 723.78%$ 723.779 millions
Second Sight Medical Products Inc721.43%$ 721.429 millions
Regulus Therapeutics Inc 704.55%$ 704.545 millions
Integrity Applications Inc 693.53%$ 693.534 millions
Insmed Inc688.33%$ 688.331 millions
Esperion Therapeutics Inc 678.26%$ 678.261 millions
Acelrx Pharmaceuticals Inc673.12%$ 673.118 millions
Dynavax Technologies Corp666.22%$ 666.222 millions
Eidos Therapeutics Inc 646.67%$ 646.667 millions
Pulse biosciences inc 640.28%$ 640.278 millions
Celgene Corp631.25%$ 631.250 millions
Lifeloc Technologies Inc628.49%$ 628.486 millions
Fluidigm Corp579.80%$ 579.798 millions
Quotient Limited572.99%$ 572.986 millions
Deciphera Pharmaceuticals Inc 565.84%$ 565.836 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

WES's Profile

Stock Price

WES's Financials

Business Description

Fundamentals

Charts & Quotes

WES's News

Suppliers

WES's Competitors

Customers & Markets

Economic Indicators

WES's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071